Market Cap 519.54M
Revenue (ttm) 99.60M
Net Income (ttm) 8.55M
EPS (ttm) N/A
PE Ratio 41.94
Forward PE 37.28
Profit Margin 8.58%
Debt to Equity Ratio 0.00
Volume 398,300
Avg Vol 900,976
Day's Range N/A - N/A
Shares Out 79.81M
Stochastic %K 46%
Beta 2.31
Analysts Strong Sell
Price Target $15.25

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 388 6706
Address:
10900 Wilshire Blvd, Suite 600, Los Angeles, United States
wycliff
wycliff Dec. 25 at 1:31 PM
$NAGE https://g.co/gemini/share/bb970cb88036
0 · Reply
ActivistInvV2
ActivistInvV2 Dec. 25 at 8:28 AM
$NAGE Forward momentum is increasingly dictated by operational clarity, given the heightened sensitivity to timeline slippage. Shortfalls would likely reprice expectations quickly.
0 · Reply
wycliff
wycliff Dec. 25 at 2:42 AM
$NAGE https://g.co/gemini/share/35e246f45e01
0 · Reply
wycliff
wycliff Dec. 25 at 2:24 AM
$NAGE https://case.edu/news/new-study-shows-alzheimers-disease-can-be-reversed-achieve-full-neurological-recovery-not-just-prevented-or-slowed-animal-models
1 · Reply
stupidusername
stupidusername Dec. 24 at 2:12 PM
$NAGE noticed a few bots popping up in here with weird vague messages. Wonder what triggered that?
0 · Reply
FutureForesight
FutureForesight Dec. 24 at 11:02 AM
$NAGE Current positioning will be tested as operational decisions reinforce credibility with the market. Momentum requires evidence, not projections.
0 · Reply
wycliff
wycliff Dec. 24 at 3:35 AM
0 · Reply
wycliff
wycliff Dec. 23 at 10:49 PM
$NAGE https://www.eatingwell.com/best-supplements-for-women-over-50-11860488#toc-4-nicotinamide-riboside
0 · Reply
wycliff
wycliff Dec. 23 at 10:45 PM
$NAGE https://x.com/niagenbio/status/2003530260055490626?s=46&t=__Y6Jc4u9xx6Yl0Ih9I5Fw
0 · Reply
dacrockett02
dacrockett02 Dec. 23 at 8:45 PM
$NAGE https://x.com/i/status/2003530260055490626
0 · Reply
Latest News on NAGE
Niagen Bioscience: High Conviction, High Expectations

Jun 11, 2025, 6:48 AM EDT - 7 months ago

Niagen Bioscience: High Conviction, High Expectations


Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript

May 10, 2025, 1:40 PM EDT - 8 months ago

Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript


ChromaDex to Present at the 37th Annual Roth Conference

Mar 11, 2025, 4:04 PM EDT - 10 months ago

ChromaDex to Present at the 37th Annual Roth Conference


ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

Mar 6, 2025, 10:30 AM EST - 10 months ago

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High


ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 8:53 PM EST - 10 months ago

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript


ChromaDex Appoints Ozan Pamir as Chief Financial Officer

Sep 20, 2024, 8:32 AM EDT - 1 year ago

ChromaDex Appoints Ozan Pamir as Chief Financial Officer


wycliff
wycliff Dec. 25 at 1:31 PM
$NAGE https://g.co/gemini/share/bb970cb88036
0 · Reply
ActivistInvV2
ActivistInvV2 Dec. 25 at 8:28 AM
$NAGE Forward momentum is increasingly dictated by operational clarity, given the heightened sensitivity to timeline slippage. Shortfalls would likely reprice expectations quickly.
0 · Reply
wycliff
wycliff Dec. 25 at 2:42 AM
$NAGE https://g.co/gemini/share/35e246f45e01
0 · Reply
wycliff
wycliff Dec. 25 at 2:24 AM
$NAGE https://case.edu/news/new-study-shows-alzheimers-disease-can-be-reversed-achieve-full-neurological-recovery-not-just-prevented-or-slowed-animal-models
1 · Reply
stupidusername
stupidusername Dec. 24 at 2:12 PM
$NAGE noticed a few bots popping up in here with weird vague messages. Wonder what triggered that?
0 · Reply
FutureForesight
FutureForesight Dec. 24 at 11:02 AM
$NAGE Current positioning will be tested as operational decisions reinforce credibility with the market. Momentum requires evidence, not projections.
0 · Reply
wycliff
wycliff Dec. 24 at 3:35 AM
0 · Reply
wycliff
wycliff Dec. 23 at 10:49 PM
$NAGE https://www.eatingwell.com/best-supplements-for-women-over-50-11860488#toc-4-nicotinamide-riboside
0 · Reply
wycliff
wycliff Dec. 23 at 10:45 PM
$NAGE https://x.com/niagenbio/status/2003530260055490626?s=46&t=__Y6Jc4u9xx6Yl0Ih9I5Fw
0 · Reply
dacrockett02
dacrockett02 Dec. 23 at 8:45 PM
$NAGE https://x.com/i/status/2003530260055490626
0 · Reply
goseahawks
goseahawks Dec. 23 at 7:26 PM
$NAGE odd drop after good news
0 · Reply
theDIOyears
theDIOyears Dec. 23 at 6:20 PM
$NAGE looking to buy back In.
0 · Reply
NathanH1
NathanH1 Dec. 23 at 8:08 AM
$NAGE when will we get the next update?
1 · Reply
wycliff
wycliff Dec. 23 at 7:49 AM
$NAGE https://www.perplexity.ai/search/eb7cf35d-d4c5-49ed-aed7-67c889f5def3
0 · Reply
wycliff
wycliff Dec. 23 at 7:42 AM
$NAGE https://www.marketbeat.com/instant-alerts/niagen-bioscience-inc-nasdaqnage-receives-average-rating-of-moderate-buy-from-brokerages-2025-12-11/
1 · Reply
justiceforb_85
justiceforb_85 Dec. 23 at 3:11 AM
$NAGE when is our next clinical trial update?
0 · Reply
wycliff
wycliff Dec. 23 at 1:38 AM
$NAGE https://d18rn0p25nwr6d.cloudfront.net/CIK-0001386570/4602e828-bd38-456c-9f6a-9a970f7d931d.pdf
0 · Reply
wycliff
wycliff Dec. 22 at 11:44 PM
$NAGE https://finance.yahoo.com/news/discover-3-elite-growth-stocks-173552176.html
0 · Reply
wycliff
wycliff Dec. 22 at 9:56 PM
$NAGE https://t.co/Yl0wKkVbkQ?ssr=true
0 · Reply
Rainmaker64
Rainmaker64 Dec. 22 at 7:16 PM
$NAGE The financial implications of this patent deal are intriguing. While I cannot find the EXACT (legacy) royalty payment to Queen’s University Belfast, multiple AI models suggest a rate between 2% and 5% of related sales. This could be upwards of 2M-5M on a related 100M revenue stream. And, this would have been much higher in 2026 as overall sales could reach 150M. This is now essentially a FIXED payment of ~$550,000 per year (2026-2038) with some 1.5M and 2.0M payments in 2035 and 2038, respectively. Aside from the highly advantageous and strategic implications on OWNING the patents, this could easily add several points to the margins next year. If the gross margin is 65% and the Net Margin is 16%-18%, 2026 could be a very good year.
2 · Reply
wycliff
wycliff Dec. 22 at 6:26 PM
$NAGE We are proud to announce that Dr. Andrew Shao, Ph.D., our Senior Vice President of Global Scientific & Regulatory Affairs, has been re-elected to the Board of Directors for the Council for Responsible Nutrition (CRN). As the dietary supplement and functional food industry prepares for the unique challenges and opportunities of 2026, Dr. Shao’s continued leadership ensures that Niagen Bioscience remains at the forefront of science-based advocacy and regulatory excellence. At Niagen Bioscience, we are committed to upholding the highest standards of safety and efficacy. Having Dr. Shao help guide the industry's leading trade association reinforces our dedication to responsible growth and consumer trust.Congratulations, Andrew, on this well-deserved re-election! Read the full announcement from CRN here: http://lnkd.in/gwhMCApW
0 · Reply
tymtested
tymtested Dec. 22 at 4:55 PM
$NAGE looks like a buying opportunity
0 · Reply